Supernus Pharmaceuticals (SUPN) to Release Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) will likely be releasing its earnings data after the market closes on Tuesday, February 25th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.46 per share and revenue of $155.25 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $33.05 on Monday. Supernus Pharmaceuticals has a 1-year low of $25.53 and a 1-year high of $40.28. The stock’s 50-day moving average is $37.48 and its 200 day moving average is $35.38. The company has a market cap of $1.82 billion, a P/E ratio of 30.89 and a beta of 0.90.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $57.00 to $36.00 in a research report on Wednesday, February 19th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.